Parnax Lab [PARNAXLAB] vs Sequent Scientific [SEQUENT] Detailed Stock Comparison
Parnax Lab
BSE
Loading...
Sequent Scientific
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Parnax Lab wins in 15 metrics, Sequent Scientific wins in 4 metrics, with 0 ties. Parnax Lab appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Parnax Lab | Sequent Scientific | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 12.99 | 153.36 | Parnax Lab |
| Price-to-Book Ratio | 1.69 | 6.20 | Parnax Lab |
| Debt-to-Equity Ratio | 83.52 | 62.47 | Sequent Scientific |
| PEG Ratio | -0.73 | 1.29 | Parnax Lab |
| EV/EBITDA | 8.04 | 29.22 | Parnax Lab |
| Profit Margin (TTM) | 5.67% | 1.85% | Parnax Lab |
| Operating Margin (TTM) | 10.29% | 7.56% | Parnax Lab |
| EBITDA Margin (TTM) | 10.29% | 7.56% | Parnax Lab |
| Return on Equity | 13.84% | 2.84% | Parnax Lab |
| Return on Assets (TTM) | 6.07% | 1.37% | Parnax Lab |
| Free Cash Flow (TTM) | $137.24M | $442.73M | Sequent Scientific |
| 1-Year Return | 10.65% | 6.29% | Parnax Lab |
| Price-to-Sales Ratio (TTM) | 0.74 | 2.73 | Parnax Lab |
| Enterprise Value | $2.07B | $48.53B | Sequent Scientific |
| EV/Revenue Ratio | 1.09 | 3.03 | Parnax Lab |
| Gross Profit Margin (TTM) | 43.83% | 46.86% | Sequent Scientific |
| Revenue per Share (TTM) | $166 | $64 | Parnax Lab |
| Earnings per Share (Diluted) | $9.43 | $1.14 | Parnax Lab |
| Beta (Stock Volatility) | 0.46 | 0.91 | Parnax Lab |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Parnax Lab vs Sequent Scientific Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Parnax Lab | 4.48% | 6.15% | 9.38% | 43.81% | 42.55% | -21.14% |
| Sequent Scientific | -0.52% | -1.29% | -0.86% | -5.35% | 15.09% | -5.81% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Parnax Lab | 10.65% | 44.25% | 647.19% | 397.20% | 828.12% | 1,483.33% |
| Sequent Scientific | 6.29% | 51.90% | 29.84% | 17.97% | 17.97% | 17.97% |
Performance & Financial Health Analysis: Parnax Lab vs Sequent Scientific
| Metric | PARNAXLAB | SEQUENT |
|---|---|---|
| Market Information | ||
| Market Cap | ₹1.41B | ₹43.69B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 5,491 | 391,055 |
| 90 Day Avg. Volume | 6,550 | 532,936 |
| Last Close | ₹133.00 | ₹173.92 |
| 52 Week Range | ₹81.00 - ₹193.50 | ₹117.35 - ₹240.70 |
| % from 52W High | -31.27% | -27.74% |
| All-Time High | ₹193.50 (Nov 04, 2024) | ₹336.50 (Jun 28, 2021) |
| % from All-Time High | -31.27% | -48.32% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.07% | 0.13% |
| Quarterly Earnings Growth | -0.18% | 1.20% |
| Financial Health | ||
| Profit Margin (TTM) | 0.06% | 0.02% |
| Operating Margin (TTM) | 0.10% | 0.08% |
| Return on Equity (TTM) | 0.14% | 0.03% |
| Debt to Equity (MRQ) | 83.52 | 62.47 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹72.57 | ₹28.19 |
| Cash per Share (MRQ) | ₹2.34 | ₹2.52 |
| Operating Cash Flow (TTM) | ₹297.41M | ₹360.47M |
| Levered Free Cash Flow (TTM) | ₹115.19M | ₹218.78M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | ₹0.00 |
Valuation & Enterprise Metrics Analysis: Parnax Lab vs Sequent Scientific
| Metric | PARNAXLAB | SEQUENT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 12.99 | 153.36 |
| Forward P/E | N/A | 34.62 |
| PEG Ratio | -0.73 | 1.29 |
| Price to Sales (TTM) | 0.74 | 2.73 |
| Price to Book (MRQ) | 1.69 | 6.20 |
| Market Capitalization | ||
| Market Capitalization | ₹1.41B | ₹43.69B |
| Enterprise Value | ₹2.07B | ₹48.53B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.09 | 3.03 |
| Enterprise to EBITDA | 8.04 | 29.22 |
| Risk & Other Metrics | ||
| Beta | 0.46 | 0.91 |
| Book Value per Share (MRQ) | ₹72.57 | ₹28.19 |
Financial Statements Comparison: Parnax Lab vs Sequent Scientific
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | PARNAXLAB | SEQUENT |
|---|---|---|
| Revenue/Sales | ₹533.76M | ₹4.41B |
| Cost of Goods Sold | ₹299.82M | ₹2.35B |
| Gross Profit | ₹233.94M | ₹2.07B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹54.94M | ₹333.50M |
| EBITDA | ₹76.21M | ₹505.30M |
| Pre-Tax Income | ₹44.55M | ₹255.20M |
| Income Tax | ₹11.80M | ₹79.50M |
| Net Income (Profit) | ₹32.75M | ₹175.70M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | PARNAXLAB | SEQUENT |
|---|---|---|
| Cash & Equivalents | ₹5.50M | ₹626.60M |
| Total Current Assets | ₹683.40M | ₹8.74B |
| Total Current Liabilities | ₹743.34M | ₹5.05B |
| Long-Term Debt | ₹262.42M | ₹3.00B |
| Total Shareholders Equity | ₹832.42M | ₹7.70B |
| Retained Earnings | N/A | ₹1.25B |
| Property, Plant & Equipment | ₹1.09B | ₹2.84B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | PARNAXLAB | SEQUENT |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | PARNAXLAB | SEQUENT |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 5,491 | 391,055 |
| Average Daily Volume (90 Day) | 6,550 | 532,936 |
| Shares Outstanding | 11.49M | 249.89M |
| Float Shares | 2.99M | 117.77M |
| % Held by Insiders | 0.74% | 0.53% |
| % Held by Institutions | 0.00% | 0.13% |
Dividend Analysis & Yield Comparison: Parnax Lab vs Sequent Scientific
| Metric | PARNAXLAB | SEQUENT |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹0.00 |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | ₹0.00 |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | ₹0.00 |
| Ex-Dividend Date | N/A | N/A |